Truist Financial Raises PT on Pheresis From $35 to $36, Keeps Buy Rating

Pheresis, Inc. (NASDAQ:PHR) is one of the 14 Best Small Cap Stocks to Buy Right Now. On September 5, Truist Financial raised the price target on Pheresis, Inc. (NASDAQ:PHR) from $35 to $36, keeping its Buy rating on the stock.

Jailendra Singh from Truist increased the price target on PHR following a post-quarter call with management to discuss its Q2 FY2026 results, full-year expectations, and acquisition of AccessOne. Singh noted that the company’s Q2 results were in line with expectations, with a total revenue of $117.3 million, up 15% from a year ago. The adjusted EBITDA was around $22 million, ahead of consensus and a notable increase of $16 million year-over-year.

Singh remains positive about Pheresis, Inc. (NASDAQ:PHR) as the company updated its FY2026 adjusted EBITDA outlook to around $87 million to $92 million, a $2 million increase at both ends of the last range. The company retained the revenue outlook at $472 million to $482 million. Moreover, Pheresis has signed a definitive agreement to acquire Access One for $160 million. Access One is a market leader in providing financing solutions for healthcare receivables, working with some of the largest health systems in the U.S. The analyst mentioned that this major development could boost the company’s addressable market by almost $6 billion.

Pheresis, Inc. (NASDAQ:PHR) provides comprehensive software solutions that enhance the operational and financial performance of healthcare organizations. The company’s solutions include SaaS-based integrated tools that manage patient access, registration, and payments.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.